Abstract
Neurogranin (Ng) is a dendritic protein associated with synaptic plasticity, proposed to be a novel biomarker to measure synaptic dysfunction and degeneration in Alzheimer’s disease. Since electroconvulsive therapy (ECT) has been suggested to facilitate neurogenesis and neural plasticity, we tested whether ECT could modify CSF Ng concentrations measured before and after a course of ECT in 12 patients with major depression. CSF Ng concentrations did not change, but baseline levels were positively correlated with the therapeutic response.
This is a preview of subscription content, log in via an institution to check access.
References
Chen SJ, Sweatt JD, Klann E (1997) Enhanced phosphorylation of the postsynaptic protein kinase C substrate RC3/neurogranin during long-term potentiation. Brain Res 749(2):181–187
Fedorov NB, Pasinelli P, Oestreicher AB, DeGraan PN, Reymann KG (1995) Antibodies to postsynaptic PKC substrate neurogranin prevent long-term potentiation in hippocampal CA1 neurons. Eur J Neurosci 7(4):819–822
Gerendasy DD, Sutcliffe JG (1997) RC3/neurogranin, a postsynaptic calpacitin for setting the response threshold to calcium influxes. Mol Neurobiol 15(2):131–163
Guadano-Ferraz A, Vinuela A, Oeding G, Bernal J, Rausell E (2005) RC3/neurogranin is expressed in pyramidal neurons of motor and somatosensory cortex in normal and denervated monkeys. J Comp Neurol 493(4):554–570. doi:10.1002/cne.20774
Inta D, Lima-Ojeda JM, Lau T, Tang W, Dormann C, Sprengel R, Schloss P, Sartorius A, Meyer-Lindenberg A, Gass P (2013) Electroconvulsive therapy induces neurogenesis in frontal rat brain areas. PLoS One 8(7):e69869. doi:10.1371/journal.pone.0069869
Joshi SH, Espinoza RT, Pirnia T, Shi J, Wang Y, Ayers B, Leaver A, Woods RP, Narr KL (2016) Structural plasticity of the hippocampus and amygdala induced by electroconvulsive therapy in major depression. Biol Psychiatry 79(4):282–292. doi:10.1016/j.biopsych.2015.02.029
Kaleka KS, Gerges NZ (2016) Neurogranin restores amyloid beta-mediated synaptic transmission and long-term potentiation deficits. Exp Neurol 277:115–123. doi:10.1016/j.expneurol.2015.12.013
Kranaster L, Aksay SS, Bumb JM, Janke C, Alonso A, Hoyer C, Zerr I, Schmitz M, Hausner L, Frolich L, Sartorius A (2016) Electroconvulsive therapy selectively enhances amyloid beta 1–42 in the cerebrospinal fluid of patients with major depression: a prospective pilot study. Eur Neuropsychopharmacol 26(12):1877–1884. doi:10.1016/j.euroneuro.2016.11.004
Kranaster L, Hoyer C, Aksay SS, Bumb JM, Leweke FM, Janke C, Thiel M, Lutz B, Bindila L, Sartorius A (2017a) Electroconvulsive therapy enhances endocannabinoids in the cerebrospinal fluid of patients with major depression: a preliminary prospective study. Eur Arch Psychiatry Clin Neurosci. doi:10.1007/s00406-017-0789-7
Kranaster L, Hoyer C, Aksay SS, Bumb JM, Muller N, Zill P, Schwarz MJ, Sartorius A (2017b) Antidepressant efficacy of electroconvulsive therapy is associated with a reduction of the innate cellular immune activity in the cerebrospinal fluid in patients with depression. World J Biol Psychiatry. doi:10.1080/15622975.2017.1355473
Kvartsberg H, Duits FH, Ingelsson M, Andreasen N, Ohrfelt A, Andersson K, Brinkmalm G, Lannfelt L, Minthon L, Hansson O, Andreasson U, Teunissen CE, Scheltens P, Van der Flier WM, Zetterberg H, Portelius E, Blennow K (2015) Cerebrospinal fluid levels of the synaptic protein neurogranin correlates with cognitive decline in prodromal Alzheimer’s disease. Alzheimer’s Dementia 11(10):1180–1190. doi:10.1016/j.jalz.2014.10.009
Mattsson N, Insel PS, Palmqvist S, Portelius E, Zetterberg H, Weiner M, Blennow K, Hansson O, Alzheimer’s Disease Neuroimaging Initiative (2016) Cerebrospinal fluid tau, neurogranin, and neurofilament light in Alzheimer’s disease. EMBO Mol Med 8(10):1184–1196. doi:10.15252/emmm.201606540
Ogden TL (2010) Handling results below the level of detection. Ann Occup Hyg 54(3):255–256. doi:10.1093/annhyg/mep099
Portelius E, Zetterberg H, Skillback T, Tornqvist U, Andreasson U, Trojanowski JQ, Weiner MW, Shaw LM, Mattsson N, Blennow K, Alzheimer’s Disease Neuroimaging Initiative (2015) Cerebrospinal fluid neurogranin: relation to cognition and neurodegeneration in Alzheimer’s disease. Brain 138(Pt 11):3373–3385. doi:10.1093/brain/awv267
Represa A, Deloulme JC, Sensenbrenner M, Ben-Ari Y, Baudier J (1990) Neurogranin: immunocytochemical localization of a brain-specific protein kinase C substrate. J Neurosci 10(12):3782–3792
Rotheneichner P, Lange S, O’Sullivan A, Marschallinger J, Zaunmair P, Geretsegger C, Aigner L, Couillard-Despres S (2014) Hippocampal neurogenesis and antidepressive therapy: shocking relations. Neural Plast 2014:723915. doi:10.1155/2014/723915
Sanfilippo C, Forlenza O, Zetterberg H, Blennow K (2016) Increased neurogranin concentrations in cerebrospinal fluid of Alzheimer’s disease and in mild cognitive impairment due to AD. J Neural Transm (Vienna) 123(12):1443–1447. doi:10.1007/s00702-016-1597-3
Sartorius A, Hellweg R, Litzke J, Vogt M, Dormann C, Vollmayr B, Danker-Hopfe H, Gass P (2009) Correlations and discrepancies between serum and brain tissue levels of neurotrophins after electroconvulsive treatment in rats. Pharmacopsychiatry 42(6):270–276. doi:10.1055/s-0029-1224162
Sartorius A, Demirakca T, Bohringer A, Clemm von Hohenberg C, Aksay SS, Bumb JM, Kranaster L, Ende G (2016) Electroconvulsive therapy increases temporal gray matter volume and cortical thickness. Eur Neuropsychopharmacol 26(3):506–517. doi:10.1016/j.euroneuro.2015.12.036
Wen Z, Chen J, Khan RA, Wang M, Song Z, Li Z, Shen J, Li W, Shi Y (2016) Polymorphisms in NRGN are associated with schizophrenia, major depressive disorder and bipolar disorder in the Han Chinese population. J Affect Disord 194:180–187. doi:10.1016/j.jad.2016.01.034
Zachrisson OC, Balldin J, Ekman R, Naesh O, Rosengren L, Agren H, Blennow K (2000) No evident neuronal damage after electroconvulsive therapy. Psychiatry Res 96(2):157–165
Acknowledgements
LK received support by the German Research Foundation (DFG Grant No. KR 4689/3-1).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
KB and HZ are co-founders of Brain Biomarker Solutions in Gothenburg AB, a GU Ventures-based platform company at the University of Gothenburg. The other authors declare that they have no conflict of interest.
Rights and permissions
About this article
Cite this article
Kranaster, L., Blennow, K., Zetterberg, H. et al. Electroconvulsive therapy does not alter the synaptic protein neurogranin in the cerebrospinal fluid of patients with major depression. J Neural Transm 124, 1641–1645 (2017). https://doi.org/10.1007/s00702-017-1802-z
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00702-017-1802-z